Newsroom | 5573 results

Sorted by: Latest

Neurology
-

Hyperfine Announces Presentation of Results from the PRIME Study Showing Portable MRI Substantially Reduces Time to Imaging in Emergency Departments

GUILFORD, Conn.--(BUSINESS WIRE)--PRIME study results show bedside portable MRI cut order-to-scan time vs conventional MRI and identified critical ED findings....
-

Zai Lab Announces Changes to Senior Leadership Team

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced changes to its senior leadership team aimed at strengthening operational performance and efficiency. As part of these changes, the Board has made the decision that Josh Smiley, President and COO, will no longer be with the Company, effective Friday, May 22. "I want to thank Josh for his contributions to Zai Lab over the past three and a half years and wish him well in his future endeavors,"...
-

LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Stefano Folli will join the Company as incoming President, Cardiopulmonary (CP), effective June 1, succeeding Franco Poletti, who will retire on July 31. Folli will partner closely with Poletti over the coming months to ensure a seamless leadership transition before assuming full responsibility for the business on August 1. Folli will join the LivaNova Executive Leadership Tea...
-

Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 at 3:10 p.m. EDT. Audio webcasts and replays of available presentat...
-

PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program

BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-b...
-

GenSight Biologics annonce les résultats de son Assemblée Générale du 19 mai 2026

PARIS--(BUSINESS WIRE)--Regulatory News : GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour le traitement des maladies neurodégénératives de la rétine et du système nerveux central, annonce que l’ensemble des 28 résolutions soumises au vote de l’Assemblée Générale Mixte des actionnaires, tenue le 19 mai 2026 et présidée par Laurence Rodriguez, Directrice...
-

GenSight Biologics Announces the Results of its Combined General Meeting of May 19, 2026

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that all 28 resolutions submitted for shareholders’ vote at the Combined Shareholders’ Meeting held on May 19, 2026, and chaired by Laurence Rodriguez, Chief Executive Officer of the Company, were approved....
-

Children’s Hospital Los Angeles Leads Region in Neurocritical NICU Care for Newborns

LOS ANGELES--(BUSINESS WIRE)--Subtle neurologic injury in newborns can be difficult to detect, but identifying this early is crucial in preventing further damage and supporting a baby’s lifelong brain development and brain health. To help protect the newborn brain, Children’s Hospital Los Angeles (CHLA) has integrated neurocritical care into its Level IV Steven & Alexandra Cohen Foundation Newborn and Infant Critical Care Unit (NICU) since 2013. One of only eight centers nationwide with ded...
-

Autobahn Therapeutics Presents New Preclinical Data at ASCP Annual Meeting Demonstrating Elunetirom Drives Robust Bioenergetic and Neuroplastic Improvements in Neuronal Cultures

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today announced the presentation of new preclinical data for elunetirom (ABX-002), the company’s lead asset currently in Phase 2 clinical development for adjunctive major depressive disorder (MDD) and bipolar depression, at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting taking place in Miami Beach, F...
-

Neurosoft Bioelectronics Closes $7.5M Oversubscribed Seed Round to Build Stretchable and Scalable Brain-Computer Interfaces

GENEVA & NEW YORK--(BUSINESS WIRE)--Neurosoft Bioelectronics closes $7.5M oversubscribed seed round to scale its soft, stretchable brain-computer interface platform....